BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...also targets PD-L1 and PD-L2. ImmuNext Inc. and Johnson & Johnson (NYSE:JNJ) had anti-VISTA mAb JNJ-61610588...
BioCentury | Sep 16, 2019
Company News

Amgen taps Hummingbird’s tech for epitope-based antibody selection

...with two internal compounds: HMBD-001, an antibody against HER3 for solid tumors, and HMBD-002, an anti-VISTA...
BioCentury | Jul 19, 2018
Tools & Techniques

Immunotherapy Matchmaking

...PD-L1, in Phase I testing for lymphoma and solid tumors. Hummingbird Bioscience Pte. Ltd. has anti-VISTA...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...tumors. At the conference, Hummingbird Bioscience Pte. Ltd. will present an abstract covering a new anti-VISTA...
BioCentury | May 14, 2015
Distillery Therapeutics

Therapeutics: V-region immunoglobulin-containing suppressor of T cell activation (VISTA); programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1

...normal expression of VISTA and PD-1. In mouse models of colon cancer and melanoma, an anti-VISTA...
...steps include developing a humanized mAb against VISTA. ImmuNext Inc. and Johnson & Johnson have anti-VISTA...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...cell tumor infiltration compared with control antibody and delayed tumor progression. Next steps include testing anti-VISTA...
BioCentury | Nov 5, 2012
Emerging Company Profile

ImmuNext: New VISTAs

...that express the ligand. We believe that VISTA works through the tumor microenvironment and that anti-VISTA...
Items per page:
1 - 7 of 7